Redeye hosts Circio's webcast in which CEO, Dr Erik Digman Wiklund, provides an overview of the late...
Redeye comments on Medrave's new contract with VGR.
Fiskars' main markets have likely remained subdued during Q1.
Cereno Scientific has taken a step closer to advancing its second asset, CS014, a novel HDAC inhibit...
DT reports Q1 results on Apr 25. Q1 may have been a bit muted, but growth is likely to pick up pace ...
Inför Q1-rapporten räknar Analysguiden med en lägre omsättning, drivet av konjunkturen och avyttring...
Redeye comments on Truecaller ahead of its Q1 results (due 7 May).
Atria is currently ramping up its EUR 160m poultry investment in Finland.
Redeye comments on the positive results from a proof-of-concept study with the veterinary candidate ...
Redeye returns with an update following Annexin’s Q1 report, which offered no surprises.
Q1e: Clean EBIT of ~SEK 37m Pulp prices move higher, demand stronger Fair value range: SEK 9-16/sh ...
The main focus on the report will be on the progress regarding the start of production for Hella and...
Hansa Biopharma has announced a consecutive quarter with robust sales and the company has secured ad...
The internal DISA program is based on the TREX1 inhibition pathway, which potentially supports the e...
Redeye comments on Modelon's news that the current CEO, Magnus Gäfvert, is set to step down from his...
Vaisala published preliminary net sales figures for Q1/24, missing our estimates with roughly 15% y/...
Q1e: We forecast ARR of DKK 297m, 13% adj. EBITDA margin Lifting '24e-'26e ARR by 3-1% and adj.
XVIVO presented the overall results from the European Heart study, based on 203 patients across 15 c...
Ascelia's confirmation yesterday that the three professional external readers has completed the imag...
Skapar ett konkurrenskraftigt bolag i regionen Samgåendet mellan Aros och Besqab skapar en av de led...